Epsilon Healthcare (ASX:EPN) announced a milestone in its international growth strategy.
Its wholly-owned subsidiary, Epsilon Pharma, has entered into a multi-year commercial manufacturing agreement with Puro New Zealand, the largest medicinal cannabis cultivator in New Zealand and the sole BioGro certified organic producer in the Australasian region.
The partnership is designed to leverage Epsilon’s highly compliant EU GMP (Good Manufacturing Practice) facilities to process Puro’s organic raw materials into finished, pharmaceutical-grade formulations.
The agreement carries an initial three-year term, with a full market launch of Puro-branded products scheduled for the United Kingdom in Q1 2026.
The UK launch serves as the primary gateway for a broader planned expansion into strategic markets across the European continent.
Puro anticipates that approximately 50% of its total 2026 annual production will be dedicated to this UK export opportunity.
At the time of reporting, Epsilon Healthcare's share price was $0.033.